

19



Europäisches Patentamt
European Patent Office
Office européen des brevets

11 Publication number:

0 282 672
A1

12

EUROPEAN PATENT APPLICATION

21 Application number: 87307370.4

51 Int. Cl.4: C07F 15/00 , A61K 31/28

22 Date of filing: 20.08.87

30 Priority: 19.02.87 JP 34512/87

43 Date of publication of application:
21.09.88 Bulletin 88/38

84 Designated Contracting States:
DE FR GB IT SE


71 Applicant: NIPPON KAYAKU KABUSHIKI
KAISHA
11-2, Fujimi 1-chome Chiyoda-ku
Tokyo 102(JP)

72 Inventor: Nowatari, Hiroyoshi
239, Iwahanamachi
Takasaki-shi(JP)
Inventor: Hayami, Hiroshi
239, Iwahanamachi
Takasaki-shi(JP)
Inventor: Kuroda, Yasuo
104-3, Yashiro Matsudamachi
Usui-gun Gunma-ken(JP)
Inventor: Yoda, Sumio
959-2, Negoyamachi
Takasaki-shi(JP)
Inventor: Takahashi, Katsutoshi
10-8-512, Kamiya-3-chome
Kita-ku Tokyo(JP)

74 Representative: Goldin, Douglas Michael et al
J.A. KEMP & CO. 14, South Square Gray's Inn
London WC1R 5EU(GB)


54 Novel platinum complexes.

57 A diamine platinum (II) complex represented by the general formula




[wherein R₁ and R₂ are each a lower alkyl group; and two X's are each a halogen atom or jointly form a group represented by

EP 0 282 672 A1



(wherein R₃ and R₄ are each a hydrogen atom or a lower alkyl group) or a group represented by



(wherein m is 1 or 2)] is useful as an anti-tumour agent. They are prepared by reacting the diamine with M₂Pthal₄ to give the dihalogenodiamine complex which can be reacted after conversion to its diaqua complex, with the appropriate dicarboxylic acid.

NOVEL PLATINUM COMPLEXES


1 BACKGROUND OF INVENTION

1. FIELD OF THE INVENTION


This invention relates to novel platinum complexes having an antitumor effect.

2. DESCRIPTION OF THE PRIOR ART

With respect to platinum complexes having an antitumor effect, cis-Platin (cis-dichlorodiamineplatinum) is already available commercially and is being applied to many cases because of its striking effect. Other platinum complexes having an antitumor effect as well are reported in several papers. Of these, platinum complexes having a straight alkyl diamine as a ligand are limited to those having a ligand represented by the general formula



(wherein R is a hydrogen atom or a substituent such as an alkyl group, a hydroxyl group or the like and n is in an integer of 1 to 3), except for a few complexes described in Inorg. Chem. Acta, 26 (1978) L13-L14. Kidani et al. also described the complexes having the diamine ligand represented by the general formula (II), in U.S. Patent 4,477,387(1984).



wherein R₁' and R₂' are the same or different and each is hydrogen, an alkyl group or an aryl group, and p is 0 or in an integer of 1 to 3). But, of these, the complexes which have the diamine ligand represented by the general formula (II) wherein p is 2 or 3, were not characterized by any analysis or biological test, at all.


As mentioned above, cis-Platin is commercially available as a platinum complex carcinostatic agent. However, cis-Platin has high renal toxicity, which possess a dose limiting factor. Therefore, in administering cis-Platin, it is requisite that a large amount of water be administered before and during the administration of cis-Platin and that cis-Platin be administered together with a diuretics and over a long period of time. Further, cis-Platin, having low solubility in water and dissolving in water slowly, is supplied at a very low concentration. Furthermore, cis-Platin has very high vomiting toxicity, posing a problem in cure. Because of these drawbacks of cis-Platin, many researches have been conducted in order to find a platinum complex having an antitumor activity which has high solubility in water, low renal toxicity and low vomiting toxicity. However, no platinum complex has been applied practically till now.

SUMMARY OF INVENTION


When a 2,3-dimethyl-1,4-butanediamine reacts with a platinum atom to form a coordination compound through the two nitrogen atoms of the diamine, there is formed a ring structure by 7 atoms including the platinum atom, namely 7-membered ring structure as shown in the formula (III) which appears later. In general, complexes having such a 7-membered ring structure are very difficult to synthesize in the usual way. As a result of an extensive research, the present inventors succeeded in the synthesis of various platinum complexes having a 2,3-dimethyl-1,4-butanediamine as a ligand and found that these complexes have an antitumor effect and that their renal toxicity and vomiting toxicity are remarkably lower than those of cis-Platin.

The present invention has been completed based on the above finding.


The present invention relates to 2,3-dimethyl-1,4-butanediamine platinum (II) complexes represented by the general formula (III)



[wherein R_1 and R_2 are each a lower alkyl group; and two X's are each a halogen atom or jointly form a group represented by



(wherein R_3 and R_4 are each a hydrogen atom or a lower alkyl group) or a group represented by




(wherein m is 1 or 2).

DETAILED DESCRIPTION OF THE INVENTION

In the above general formula (III), the lower alkyls represented by R_1 , R_2 , R_3 and R_4 include, for example, alkyl groups of 1 to 4 carbon atoms. Specifically, there are mentioned a methyl group, an ethyl group, an n-propyl group, an isopropyl group, etc.

In the general formula (III), the halogen atom represented by X include Cl, Br, etc.

Of the compounds of the present invention represented by the formula (III), preferably are those where two X's jointly form a group represented by




Typical examples of the compounds represented by the general formula (III) are shown below. However, the present invention is not restricted to these Examples.

1. Cis-Dichloro-2,3-dimethyl-1,4-butanediamine platinum.
2. cis-Oxalato-2,3-dimethyl-1,4-butanediamine platinum.
3. cis-Malonato-2,3-dimethyl-1,4-butanediamine platinum.
4. cis-Cyclobutane-1,1-dicarboxylato-2,3-dimethyl-1,4-butanediamine platinum.
5. cis-Dimethylmalonato-2,3-dimethyl-1,4-butanediamine platinum.
6. cis-4-Oxacyclohexane-1,1-dicarboxylato-2,3-dimethyl-1,4-butanediamine platinum.
7. cis-Ethylmalonato-2,3-dimethyl-1,4-butanediamine platinum.
8. cis-Diethylmalonato-2,3-dimethyl-1,4-butanediamine platinum.

9. cis-Dichloro-2,3-diethyl-1,4-butanediamine platinum.


The compounds of the present invention can be produced by utilizing a known process, for example, a process described in Indian J. Chem., 8, 193(1970) but it is necessary to modify the reaction method.

The compounds of the present invention can be produced by reacting a diamine represented by the
5 general formula





(wherein R₁ and R₂ have the same definition as given previously, respectively) with
M₂Pt(Hal)₄

(where M is an atom capable of becoming a monovalent cation and Hal is a halogen atom) to obtain a
dihalogenodiamine platinum complex represented by the general formula



(wherein R₁ and R₂ and Hal have the same definitions as given previously, respectively) and, as necessary,
reacting the dihalogenodiamine platinum complex with silver ions in the presence of water to convert to a
diaquacomplex and reacting the diaquacomplex with a dicarboxylic acid or a salt thereof.

The production process of the compounds of the present invention will be described in more detail.




(IIIa)

(In the above, M is an atom capable of becoming a monovalent cation, such as Na, K, Cs, or the like; Hal is
a halogen atom such as Cl, Br, I, or the like; R₁ and R₂ have the same definitions as given previously,
respectively.)

As shown in the above reaction scheme, a tetrahalogenoplatinate and diamine are reacted in an
aqueous medium, preferably water to obtain a dihalogenodiamine platinum. Water is used in an amount of
preferably 5 to 500 liters, more preferably 5 to 160 liters, particularly preferably 20 to 80 liters per 1 mole of
the tetrahalogenoplatinate. The diamine is used in an amount of preferably 0.5 to 4 moles, particularly
preferably 0.9 to 1.2 moles per 1 mole of the tetrahalogenoplatinate. This reaction is conducted at 0° to
100°C, preferably 50° to 70°C with stirring. In conducting the reaction, it is preferable that an aqueous
tetrahalogenoplatinate solution and an aqueous diamine solution are gradually added to distilled water
separately at the same time. The addition is conducted preferably slowly and usually takes 1 to 6 hours.


The reaction can be conducted in an atmosphere of air but preferably under a stream of an inert gas such as nitrogen or the like.

Next, as shown in the following reaction scheme, the dihalogenodiamine platinum (IIIa) is suspended in water and reacted with silver ions and the resulting silver halide precipitate is removed by filtration to obtain an aqueous solution of a diaquacomplex (IV).



The water for suspending the dihalogenodiamine complex (IIIa) can be used in an appropriate amount but the amount preferably is 5 to 150 liters per 1 mole of the complex (IIIa). The amount of silver ion has no particular restriction but, from an economic standpoint, is preferred to be 0.5 to 6 equivalents per 1 equivalent of the dihalogenodiamine complex (IIIa). In order to avoid an excessive addition, the amount particularly preferably is 1.9 to 2 equivalents per 1 equivalent of the dihalogenodiamine complex (IIIa). The reaction is conducted at 0° to 100°C, preferably 60° to 80°C with stirring. As the compound generating silver ion, there can be used, for example, silver nitrate, silver sulfate, silver perchlorate and silver acetate.

Finally, the diaquacomplex (IV) is reacted with a dicarboxylic acid salt, a dicarboxylic acid monohydrogen salt or a dicarboxylic acid. For example, the reaction is carried out by adding an aqueous solution containing an appropriate amount of a dicarboxylic acid salt, a dicarboxylic acid monohydrogen salt or a dicarboxylic acid to the aqueous solution of the diaquacomplex (IV). Said salt or acid is used in an amount of preferably 0.5 to 10 moles, particularly preferably 0.9 to 6 moles per 1 mole of the diaquacomplex (IV). The reaction can be conducted at 0° to 100°C but preferably is conducted at 40° to 90°C to obtain a compound (IIIb).



(In the above, X' is same as X other than halogen atoms.)

The structure of the compounds (III) of the present invention was confirmed by various analytical methods such as elemental analysis, infrared absorption spectrometry, fast atom bombardment mass spectrometry (FAB-MS Pt¹⁹⁴) and the like.

The compounds of the present invention have very low renal toxicity and very low vomiting toxicity, have high solubility in water, are dissolved in water rapidly, have an excellent antitumor effect, and accordingly are useful as an antitumor agent. When they are used as an antitumor agent, they can be administered as an injection, an oral drug and the like. Moreover, the compounds of the present invention are stable in air at room temperature, thus requiring no low temperature storage.

The embodiments of the present invention will be described below by way of Examples. However, the present invention is in no way restricted to these Examples.

Example 1

cis-Dichloro-2,3-dimethyl-1,4-butanediamine Platinum (Compound No. 1)

10 g of potassium tetrachloroplatinate (II) was dissolved in 350 ml of water. Thereto was added a solution of 16 g of potassium iodide dissolved in 50 ml of water, with stirring. Stirring was continued for 5 minutes at 35°C to obtain a black aqueous solution of potassium tetraiodoplatinate (II). Separately, 2.80 g of 2,3-dimethyl-1,4-butanediamine was dissolved in 400 ml of water to obtain an aqueous 2,3-dimethyl-1,4-butanediamine solution. 250 ml of water was placed in a flask then stirred at 60°C under nitrogen atmosphere. Into this water, were dropwise added the aqueous potassium tetraiodoplatinate (II) solution and the aqueous 2,3-dimethyl-1,4-butanediamine solution both prepared above, simultaneously for 2 hours at the constant rates, respectively. The reaction was carried out with stirring at 60°C. The resulting reddish brown crystals were collected by filtration and washed with water, ethanol and ether in this order. The crystals were then dried under vacuum to obtain 10.13 g (yield: 74.4%) of crystals of cisdiiodo-2,3-dimethyl-1,4-butanediamine platinum.

1 g of this product was suspended in 20 ml of water. Thereto was added a solution of 589 mg of silver nitrate dissolved in 10 ml of water. They were stirred for 20 minutes at 60°C for reaction. The reaction mixture was cooled to room temperature and filtrated to remove silver iodide. The silver iodide removed was washed with water. The filtrate and the washings were mixed together, and thereto was added a solution of 620 mg of sodium chloride dissolved in 5 ml of water. The mixture was stirred for 10 minutes at room temperature. The resulting yellow crystals were collected by filtration, washed with a small amount of water of 0°C and then with ethanol, and dried under vacuum to obtain a compound No. 1.

Yield: 299 mg

Elementary analysis

Calculated (%):

C, 18.86; H, 4.22; N, 7.32; Pt, 51.04

Found (%):

C, 18.63; H, 4.39; N, 7.18; Pt, 50.6

FAB-MS: $(M + H)^+ = 381$

Example 2

cis-Oxalato-2,3-dimethyl-1,4-butanediamine Platinum (Compound No. 2)

In Example 1, 620 mg of sodium chloride was replaced by 652 mg of potassium oxalate monohydrate. After addition of a solution of 652 mg of this potassium oxalate monohydrate in 5 ml of water, the resulting mixture was stirred for 2 hours at 60°C. The resulting mixture was concentrated to 5 ml and then cooled to 0°C. The resulting white crystals were collected by filtration, washed with a small amount of water of 0°C and then with ethanol, and dried under vacuum to obtain a compound No. 2.

Yield: 398 mg

Elementary analysis

Calculated (%):

C, 24.06; H, 4.04; N, 7.02; Pt, 48.85

Found (%):

C, 24.22; H, 4.28; N, 7.31; Pt, 49.0

FAB-MS: $(M + H)^+ = 399$

Example 3

cis-Malonato-2,3-dimethyl-1,4-butanediamine Platinum (Compound No. 3)

In Example 1, the solution of 620 mg of sodium chloride dissolved in 5 ml of water was replaced by a solution obtained by dissolving 368 mg of malonic acid in 6.37 ml of 1 N aqueous sodium hydroxide solution. The mixture resulting from addition of this solution was stirred for 3 hours at 50°C for reaction. The reaction mixture was concentrated to 5 ml and then cooled to 0°C. The resulting white crystals were collected by filtration, washed with a small amount of water of 0°C and then with ethanol, and dried under vacuum to obtain a compound No. 3.

Yield: 243 mg

Elementary analysis

Calculated (%):

C, 26.15; H, 4.39; N, 6.78; Pt, 47.20

Found (%):

5 C, 26.40; H, 4.11; N, 6.65; Pt, 47.9

FAB-MS: $(M + H)^+ = 413$

Example 4

10

cis-Cyclobutane-1,1-dicarboxylato-2,3-dimethyl-1,4-butanediamine Platinum (Compound No. 4)

In Example 1, the solution of 620 mg of sodium chloride dissolved in 5 ml of water was replaced by a solution obtained by dissolving 510 mg of 1,1-cyclobutanedicarboxylic acid in 6.90 ml of 1 N aqueous sodium hydroxide solution. The mixture resulting from addition of this solution was stirred for 2 hours at 60°C for reaction. The reaction mixture was concentrated to 5 ml and then cooled to 0°C. The resulting white crystals were collected by filtration, washed with a small amount of water of 0°C and then with ethanol, and dried under vacuum to obtain a compound No. 4.

Yield: 330 mg

20 Elementary analysis

Calculated (%):

C, 31.79; H, 4.89; N, 6.18; Pt, 43.03

Found (%):

C, 32.01; H, 4.67; N, 6.34; Pt, 44.0

25 FAB-MS: $(M + H)^+ = 453$

Example 5

30 cis-Dimethylmalonato-2,3-dimethyl-1,4-butanediamine Platinum (Compound No. 5)

In Example 1, the solution of 620 mg of sodium chloride dissolved in 5 ml of water was replaced by a solution obtained by dissolving 468 mg of dimethylmalonic acid in 6.90 ml of 1 N aqueous sodium hydroxide solution. The mixture resulting from addition of this solution was stirred for 2 hours at 60°C for reaction. The reaction mixture was concentrated to 5 ml and then cooled to 0°C. The resulting white crystals were collected by filtration, washed with a small amount of water of 0°C and then with ethanol, and dried under vacuum to obtain a compound No. 5.

Yield: 230 mg

Elementary analysis

40 Calculated (%):

C, 29.93; H, 5.02; N, 6.35; Pt, 44.20

Found (%):

C, 30.11; H, 5.30; N, 6.08; Pt, 44.9

FAB-MS: $(M + H)^+ = 441$

45

Example 6

50 cis-4-Oxacyclohexane-1,1-dicarboxylato-2,3-dimethyl-1,4-butanediamine Platinum (Compound No. 6)

In Example 1, the solution of 620 mg of sodium chloride dissolved in 5 ml of water was replaced by a solution obtained by dissolving 616 mg of 4-oxacyclohexane-1,1-dicarboxylic acid in 6.90 ml of 1 N aqueous sodium hydroxide solution. The mixture resulting from addition of this solution was stirred for 2 hours at 60°C for reaction. The reaction mixture was concentrated to 5 ml and then cooled to 0°C. The resulting white crystals were collected by filtration, washed with a small amount of water of 0°C and then with ethanol, and dried under vacuum to obtain a compound No. 6.

Yield: 252 mg

Elementary analysis

Calculated (%):

C, 32.30; H, 5.00; N, 5.79; Pt, 40.35

Found (%):

C, 32.48; H, 4.86; N, 5.92; Pt, 41.4

5 FAB-MS: $(M + H)^+ = 483$

Example 7

10 cis-Ethylmalonato-2,3-dimethyl-1,4-butanediamine Platinum (Compound No. 7)

In Example 1, the solution of 620 mg of sodium chloride dissolved in 5 ml of water was replaced by a solution obtained by dissolving 468 mg of ethylmalonic acid in 6.90 ml of 1 N aqueous sodium hydroxide solution. The mixture resulting from addition of this solution was stirred for 2 hours at 60°C for reaction. The
15 reaction mixture was concentrated to 5 ml and then cooled to 0°C. The resulting white crystals were collected by filtration, washed with a small amount of water of 0°C and then with ethanol, and dried under vacuum to obtain a compound No. 7.

Yield: 307 mg

Elementary analysis

20 Calculated (%):

C, 29.93; H, 5.02; N, 6.35; Pt, 44.20

Found (%):

C, 30.01; H, 4.98; N, 6.16; Pt, 43.7

FAB-MS: $(M + H)^+ = 441$

25

Example 8

cis-Diethylmalonato-2,3-dimethyl-1,4-butanediamine Platinum (Compound No. 8)

30

In Example 1, the solution of 620 mg of sodium chloride dissolved in 5 ml of water was replaced by a solution obtained by dissolving 567 mg of diethylmalonic acid in 6.90 ml of 1 N aqueous sodium hydroxide solution. The mixture resulting from addition of this solution was stirred for 2 hours at 60°C for reaction. The
35 reaction mixture was concentrated to 5 ml and then cooled to 0°C. The resulting white crystals were collected by filtration, washed with a small amount of water of 0°C and then with ethanol, and dried under vacuum to obtain a compound No. 8.

Yield: 383 mg

Elementary analysis

Calculated (%):

40 C, 33.26; H, 5.58; N, 5.97; Pt, 41.56

Found (%):

C, 33.08; H, 5.26; N, 6.01; Pt, 40.6

FAB-MS: $(M + H)^+ = 469$

The physical characteristics of the compounds of the present invention are shown in Table 1.

45

50

55

Table 1

Compound No.	Solubility in water (mg/ml)	IR absorption spectrum (cm ⁻¹)	
		N-H	C=O
1	>2*	3230-3130	-
2	>3	3240-3130	1700-1640
3	>30	3230-3120	1660-1630
4	>5	3230-3130	1630-1590
- Cont'd -			

Table 1 (Cont'd)

5	>20	3240-3200	1640-1610
6	>20	3200-3130	1660-1630
7	>20	3220-3140	1680-1620
8	>15	3230-3120	1670-1610

* Solubility in physiological saline solution

In view of the fact that cis-Platin has solubility of about 1.2 mg/ml in physiological saline solution, the present compounds apparently have high solubility in water. In addition, the present compounds are dissolved in water quickly. Therefore, when used as an injection, the crystals of the present compounds can be dissolved in water prior to administration and the resulting aqueous solutions can be administered immediately after dissolution.

Next, the antitumor activities of the present compounds will be described by way of Experimental Examples.

Experimental Example 1

Test of growth inhibitory activity against various kinds of cultured tumor cells

(Test method)

Mouse leukemia L1210 cells were cultured in a RPMI 1640 medium containing 10% of fetal calf serum and mouse Lewis lung carcinoma (LL) cells were cultured in a RPMI 1640 medium containing 10% fetal calf serum and 100 μ g/ml of Kanamycin. Inhibition percentage (%) of growth on each tumor cells was calculated from the number of cells in the cases of addition and no addition of each compound, and IC₅₀ value (a concentration at which growth was inhibited by 50%) was obtained from a graph prepared by plotting a concentration of compounds and the inhibition percentage on logarithmic probability paper.

The results are shown in Table 2.

Table 2

Compound No.	IC ₅₀ (μg/ml)	
	Tumor cell L1210	Tumor cell LL
1	0.04	0.43
2	0.11	0.65
3	0.27	0.95
4	1.01	2.10
5	0.40	1.06
6	0.11	1.06

As is obvious from Table 2, the compounds of the present invention show an inhibition activity on the growth of tumor cells at a low concentration.

The present compounds show an excellent inhibition activity also on the growth of cis-Platin resistant tumor cells which have acquired a resistance to cis-Platin as a result of its administration. An experimental example on this activity will be described as follows.

Experimental Example 2

Test of growth inhibitory activity against cis-Platin resistant tumor cells

(Test method)

1 x 10⁵ mouse leukemia L1210 cells or 1 x 10⁵ mouse leukemia P388 cells were inoculated into the abdominal cavities of CDF, female mice. After 2 days from the inoculation, 6 mg/kg of cis-Platin was administered to them intraperitoneally. After 5 days, their tumor cells were inoculated to the abdominal cavities of other CDF, female mice, and the same treatment was applied. By repeating this procedure, cis-Platin resistant tumor cells were obtained.

Using the tumour cells thus obtained, a test for growth inhibition activity was conducted in the same manner as in Experimental Example 1, whereby IC₅₀ for cis-Platin resistant tumor cells (hereinafter referred to as IC₅₀R) was obtained. Then, the ratio of this IC₅₀R to IC₅₀ for tumor cells having no cis-Platin resistance, namely IC₅₀R/IC₅₀ was calculated.

The results are shown in Table 3.

Table 3

Compound No.	IC ₅₀ R/IC ₅₀	
	Tumor cell L1210	Tumor cell P388
cis-Platin	18.0	8.0
3	1.3	4.6
5	1.4	6.2

As is obvious from Table 3, the present compounds show an inhibition activity also on the growth of cis-Platin resistant tumor cells at a low concentration.

5 Experimental Example 3

Test of antitumor activity against mouse leukemia L1210 in vivo

(Test method)

10

1 x 10⁵ mouse leukemia L1210 cells were inoculated into the abdominal cavities of 6-week-old female CDF₁ mice. From the next day, a compound was administered to them intraperitoneally once a day for 5 consecutive days. Mice of a compound-non-treated group (control group) were administered with physiological saline solution in the same manner. The mean survival time of the compound-treated group and the control group were measured and T/C was calculated from the equation (1):

15

$$\frac{T}{C} = \frac{\text{Mean survival time of compound-treated group}}{\text{Mean survival time of control group}} \times 100 \quad (1)$$

20

When any mouse died during the test due to the acute toxicity of the compound administered, 50% lethal dose (LD₅₀) was calculated according to the conventional method.

25

The results are shown in Table 4. In Table 4, max (T/C) means the maximum value of T/C and optimum dose (Opt. dose) means a daily administration amount giving the max (T/C), namely, an optimum daily administration amount.

Table 4

30

Compound No.	max (T/C)	Opt. dose (mg/kg)	LD ₅₀ (mg/kg)
1	323	2.0	3.0
2	296	4.0	7.2
3	400	16.0	-
4	328	32.0	-
5	245	32.0	-

35

40

45

As is obvious from Table 4, the compounds of the invention have a life prolongation effect for mice inoculated with mouse leukemia L1210 cells.

The compounds of the present invention have life prolongation effects also for mice inoculated with tumor cells other than mouse leukemia L1210 cells. These effects will be explained in Experimental Example 4.

50

Experimental Example 4

Test of antitumor activity against mouse Lewis lung carcinoma

55

(Test method)

1 x 10⁶ mouse Lewis lung carcinoma cells were inoculated into the abdominal cavities of 6-week-old male BDF₁ mice. From the next day, a compound was administered to them intraperitoneally once a day for 5 consecutive days. Mice of compound-non-treated group (control group) were administered with physiological saline solution in the same manner. From the median survival time of the compound-treated group and the control group, T/C was calculated according to the following equation (2):

$$\frac{T}{C} = \frac{\text{Median survival time of compound-treated group}}{\text{Median survival time of control group}} \times 100 \quad (2)$$

The results are shown in Table 5. In Table 5, max (T/C), and Opt. dose and LD₅₀ mean the same ones in Table 4, respectively.

Table 5

Compound No.	max (T/C)	Opt. dose (mg/kg)	LD ₅₀ (mg/kg)
3	234	32.0	-
4	144	32.0	48.0

As is obvious from Table 5, the compounds of the invention have a life prolongation effect for mice inoculated with mouse Lewis lung carcinoma cells.

Next, the renal toxicity of the present compounds will be described by way of an Experimental Example.

Experimental Example 5

Test of renal toxicity

(Test method)

A compound was singly administered to 6-week-old male CDF₁ mice intraperitoneally. After 4 days, their blood was collected for measurement of blood urea nitrogen concentration (BUN value).

The results are shown in Table 6. The optimum dose of cis-Platin was 4 mg/kg according to the test method of Example 3, but in this renal toxicity test, a BUN value which is much higher than the normal value (30 mg/dl or lower) was seen when cis-Platin was administered in an amount of four times of the optimum dose. Based on this fact, as shown in Table 6, the administration amount of the present compound employed in this Experimental Example was fixed to four times of the optimum dose obtained in Experimental Example 3. In Table 6, body weight ratio is a ratio of body weight on the fourth day from administration to body weight on the administration day.

Table 6

Compound No.	Administration amount (mg/kg)	Body weight ratio	BUN value (mg/dl)
Physiological saline solution	-	1.05	22.7
cis-Platin	16	0.72	92.9
1	8	0.79	12.7
2	16	0.77	11.2

- Cont'd -

Table 6 (Cont'd)

3	64	1.00	26.4
4	128	0.89	16.4
5	128	0.89	18.8


As is obvious from Table 6, the values obtained when the present compounds were administered are very lower than the value obtained when commercially available cis-Platin was administered, and are close to the value obtained when physiological saline solution was administered. This indicates that the present compounds have very low renal toxicity. Accordingly, the present compounds can be used as antitumor agents with very low renal toxicity. In view of this characteristic and high solubility in water, the present compounds, when intravenously injected, can be applied not only in continuous administration but also in bolus administration.

Some of the present compounds have, as a ligand, a diamine having an asymmetric carbon atom. Those optical isomers obtained by optical resolution, can be applied as same as the racemic ones.


The compounds of the present invention show growth inhibition activities on the tumor cells at low concentrations and accordingly have very excellent antitumor effects against various kinds of tumors. The present compounds have high solubility in water and are quickly dissolved in water. The present compounds have low renal toxicity and low vomiting toxicity. Further, the present compounds are mild with respect to bone marrow toxicity which is generally seen with the conventional platinum complex antitumor agents; that is, the decrease in the number of white blood cells occurs mainly and their toxicity to platelets is very slight. Furthermore, recovery to normal conditions is very rapid and accordingly control is easy when the present compounds are used as an antitumor agent. Based on the fact, the present compounds can be used as an excellent antitumor agent. Moreover, the present compounds are stable in air at room temperature, thus requiring no low temperature storage.

Claims


1. A diamine platinum (II) complex represented by the general formula



15 [wherein R₁ and R₂ are each a lower alkyl group; and two X's are each a halogen atom or jointly form a group represented by



25 (wherein R₃ and R₄ are each a hydrogen atom or a lower alkyl group) or a group represented by



(wherein m is 1 or 2).


35 2. A diamine platinum (II) complex according to Claim 1, wherein R₁ and R₂ are each a methyl group.

3. A diamine platinum (II) complex according to Claim 1 or 2, wherein two X's jointly form a group represented by




45 (wherein R₃ and R₄ are each a hydrogen atom or a lower alkyl group).

4. A diamine platinum (II) complex according to Claim 1 or 2, wherein two X's jointly form a group represented by




55 5. A diamine platinum (II) complex according to Claim 1 or 2, wherein two X's jointly form a group represented by




6. A compound according to claim 1 which is cis-malonato-2,3-dimethyl-1,4-butanediamine platinum, cis-dimethylmalonato-2,3-dimethyl-1,4-butanediamine platinum, cis-cyclobutane-1,1-dicarboxylato-2,3-dimethyl-1,4-butanediamine platinum or cis-4-oxacyclohexane-1,1-dicarboxylato-2,3-dimethyl-1,4-butanediamine platinum.


7. A process for producing a compound as defined in any one of the preceding claims which comprises reacting a diamine of the formula:



with a platinum compound of the formula $\text{M}_2\text{Pt}(\text{hal})_2$, where R_1 and R_2 are as defined in any one of the preceding claims, M is an atom capable of becoming a monovalent cation and hal is halogen, to give a dihalogenodiamine compound of formula:



and, optionally, reacting the dihalogenodiamine compound with silver ions in the presence of water to convert it to a diaqua complex and reacting the diaqua complex with a dicarboxylic acid of the formula $(\text{COOH})_2$ or $\text{R}_3\text{R}_4\text{C}(\text{COOH})_2$ or



where R_3 , R_4 and m are as defined in any one of the preceding claims.

8. A pharmaceutical composition comprising a compound according to any one of claims 1 to 6 together with a pharmaceutically acceptable carrier or diluent.

9. A compound according to any one of claims 1 to 6 for use in a method of surgery or therapy practised on the human or animal body or in a method of diagnosis practised on the human or animal body.

10. A compound according to any one of claims 1 to 6 for use in the treatment of tumours.



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 87 30 7370

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)
A	EP-A-0 041 644 (BRISTOL-MYERS CO.) * Page 3 *	1	C 07 F 15/00 A 61 K 31/28
D,A	EP-A-0 055 300 (OTSUKA CHEMICAL CO.) * Claims *	7	
			TECHNICAL FIELDS SEARCHED (Int. Cl. 4)
			C 07 F 15/00 A 61 K 31/00
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 14-06-1988	Examiner PAUWELS G.R.A.
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			